Epilepsy with myoclonic absences is a recognised epileptic syndrome in which effective seizure control is the primary clinical objective. Antiseizure medications (ASMs) are the established treatment modality for this condition.
Control of myoclonic absence seizures.
Antiseizure medications remain the foundation of management. Certain first-line agents — which may be used alone or in combination — are available, with particular combinations demonstrating especially strong seizure control. The complete agent selection, sequencing, and evidence-based algorithm are detailed in the full protocol.